rather, patients and providers should focus on identifying medications with acceptable tolerability profiles and implementing strategies to minimize gastrointestinal symptoms during treatment initiation and dose escalation
Several studies found that GLP-1RAs might have direct effects on adipogenesis, lipotoxicity, fatty acid oxidation, cytokines related to hepatitis and fibrosis, and intestinal microbiota (193, 195)
These medications work by mimicking the natural GLP-1 hormone, which helps regulate appetite and food intake
You wont know until you try
-24% body weight documented over 24 weeks in Phase 2 trials
470,478,482,483,484 GLP-1RAs in the digestive system Treatment with GLP-1RAs can alleviate insulin signaling by reducing the phosphorylation of Akt protein (Decreased Akt-P) and activating Protein Kinase C- (PKC-)